ישראל - עברית - Ministry of Health

trima israel pharmaceutical products maabarot ltd - cabergoline - טבליה - cabergoline 0.5 mg - dopa and dopa derivatives - treatment of hyperprolactinemic disorders.cabotrim is indicated for the treatment of dysfunctions associated with hyperprolactinemia, including amenorrhea, oligomenorrhea, anovulation and galactorrhea. cabotrim is indicated in patients with prolactin-secreting pituitary adenomas (micro-and macroprolactinomas), idiopathic hyperprolactinemia, or empty sella syndrome with associated hyperprolactinemia. inhibition and supression of lactation .

ישראל - עברית - Ministry of Health

trima israel pharmaceutical products maabarot ltd - cabergoline 1 mg - tablets - dopa and dopa derivatives - parkinson`s disease. combination therapy with l-dopa and as monotherapy for newly diagnosed illness.

ישראל - עברית - Ministry of Health

teva israel ltd - carbidopa; levodopa - טבליה - levodopa 250 mg; carbidopa 25 mg - levodopa - levodopa - for the relief of symptoms associated with parkinson's disease.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - carbidopa; levodopa - טבליה - levodopa 250 mg; carbidopa 25 mg - levodopa - levodopa - for the relief of symptoms associated with parkinson's disease.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - benserazide as hydrochloride 25 mg; levodopa 100 mg - capsules - levodopa - for the relief of symptoms associated with parkinson's disease.

ישראל - עברית - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - carbidopa as monohydrate; levodopa - ג'ל - levodopa 20 mg/ml; carbidopa as monohydrate 5 mg/ml - levodopa - levodopa - treatment of advanced levodopa-responsive parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of parkinson medicinal products have not given satisfactory results. a positive test of the clinical response to duodopa administered via a temporary nasoduodenal tube is required before a permanent tube is inserted.

ישראל - עברית - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - טבליות מצופות פילם - carbidopa as monohydrate 18.75 mg; entacapone 200 mg; levodopa 75 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.

ישראל - עברית - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - טבליות מצופות פילם - levodopa 125 mg; entacapone 200 mg; carbidopa as monohydrate 31.25 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.

ישראל - עברית - Ministry of Health

organon pharma israel ltd., israel - carbidopa as monohydrate; levodopa - טבליות בשחרור מבוקר - levodopa 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - idiopathic parkinson's disease. postencephalitic parkinsonism. symptomatic parkinsonism. to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.